Haikang Medicine: The concerted action shareholders collectively reduce their holdings by 10 million shares, cashing out approximately 521 million yuan

Log in to the Sina Finance app and search 【information disclosure】 to view more performance evaluation tiers

Hisaco Pharmaceutical Group Co., Ltd. (hereinafter referred to as “Hisaco Pharmaceutical”) announced on April 7 that part of its shareholders holding more than 5% of the company’s shares completed the implementation of the share reduction plan. The shares reduced are by Hao Congmei and Yang Fei, who are acting in concert with one of the company’s shareholders holding more than 5%. In total, 10 million shares were reduced, accounting for 0.89% of the company’s total share capital. The amount of cash raised was approximately RMB 521 million.

Share reduction plan completed: total reduction of 10 million shares

According to the announcement, Hisaco Pharmaceutical previously disclosed on February 3, 2026, the “Pre-announcement of the reduction plan of shares by an acting-in-concert person of certain shareholders holding more than 5%” . Hao Congmei and Yang Fei planned to, within three months after the fifteen trading days from the date of disclosure of the announcement, reduce the company’s shares in total by no more than 10 million shares through block trading or centralized bidding, with the total reduction ratio not exceeding 0.89% of the company’s total share capital. Specifically, Hao Congmei planned to reduce no more than 2 million shares (representing 0.18% of the total share capital), while Yang Fei planned to reduce no more than 8 million shares (representing 0.71% of the total share capital).

Recently, the company received a notification letter from Hao Congmei and Yang Fei regarding the completion of the implementation of the share reduction plan. The above share reduction plan has been fully implemented. The actual number of shares reduced matches the pre-announced reduction plan, and has not exceeded the upper limit of the plan.

Reduction details: mainly centralized bidding transactions, average price range 48–53.14 yuan

Based on the reduction information disclosed in the announcement, Hao Congmei and Yang Fei both completed the share reduction through centralized bidding transactions. The specific details are as follows:

Based on calculations, Hao Congmei’s share reduction generated cash proceeds of approximately RMB 96 million (2 million shares × RMB 48 per share), while Yang Fei’s share reduction generated cash proceeds of approximately RMB 425 million (8 million shares × RMB 53.14 per share). In total, the two parties cashed out approximately RMB 521 million.

Change in shareholdings before and after the reduction: Hao Congmei and Yang Fei’s shareholding ratios decline

After the completion of this share reduction, the shareholding situation of Hao Congmei, Yang Fei, and their concerted action persons changed. Specifically:

Before the reduction, Hao Congmei held 3.52M shares of the company, accounting for 0.31% of the total share capital. After the reduction, her shareholding number decreased to 1.52M shares, accounting for 0.14% of the total share capital, and all of the shares are shares with no selling restrictions.

Before the reduction, Yang Fei held 42.4423 million shares of the company, accounting for 3.79% of the total share capital. After the reduction, his shareholding number decreased to 34.4423 million shares, accounting for 3.08% of the total share capital. Similarly, all of the shares are shares with no selling restrictions.

In addition, Hao Congmei’s acting-in-concert person, Zheng Wei, and Yang Fei’s acting-in-concert person did not participate in this share reduction, and their shareholding numbers and proportions did not change. Among them, Zheng Wei in total holds 154 million shares (representing 13.76% of the total share capital), while Yang Fei’s acting-in-concert person holds 217 million shares in total (representing 19.40% of the total share capital).

Impact on the company: no effect on control or operations

The announcement states that this share reduction strictly complied with laws and regulations such as the Securities Law and the Provisional Measures for the Administration of Share Reductions by Shareholders of Listed Companies. The company has made a pre-disclosure as required, and the share reduction situation is consistent with the plan. This share reduction will not lead to any change in the company’s control, and will not affect the company’s corporate governance structure, equity structure, or ongoing operations.

Hisaco Pharmaceutical states that it will continue to monitor changes in shareholders’ shareholdings and fulfill its information disclosure obligations in a timely manner in accordance with relevant regulations.

(Data source: announcement of Hisaco Pharmaceutical Group Co., Ltd.)

Disclaimer: The market carries risks; investment requires caution. This article is automatically published by an AI large model based on third-party databases and does not represent the views of Sina Finance. Any information appearing in this article is for reference only and does not constitute personal investment advice. If there are discrepancies, please refer to the actual announcements. If you have any questions, please contact biz@staff.sina.com.cn.

Click to view the full text of the original announcement >>

A wealth of information and precise analysis—available in the Sina Finance app

Responsible editor: Xiao Lang Express